Publications
Publications
Show Results For
- All HBS Web
(236)
- Faculty Publications (38)
←
Page 2 of 38
Results
- December 2014 (Revised October 2015)
- Case
Susie Mulder at NIC+ZOE
By: David Fubini, Joshua Margolis and Kerry Herman
Susie Mulder must decide how to lead NIC+ZOE—the women's apparel brand she had recently joined as CEO—from its start-up phase into a disciplined growth phase. With growing revenues, a successful product line, and savvy private equity investors, NIC+ZOE seems perfectly... View Details
- February 2013 (Revised March 2013)
- Case
Agero: Enhancing Capabilities for Customers
By: Robert Simons and Natalie Kindred
This case illustrates the importance of choosing a primary customer as the basis for organization design. Cross Country Group managers adjusted resource allocation, organization design and performance measures over time to transform Cross Country Group from an... View Details
Keywords: Entrepreneurial Management; Entrepreneurial Gap; Entrepreneurship; Auto Industry; Insurance; Performance Management; Performance Measurement; Performance Measures; Performance Pressure; Decisions; Family Business; Resource Allocation; Organizational Design; Customer Focus and Relationships; Performance Evaluation; Growth and Development Strategy; Service Industry
- June 2010 (Revised December 2013)
- Supplement
Hang Lung Properties and the Chengdu Decision (B)
By: John D. Macomber, Michael Shih-Ta Chen and Keith Chi-Ho Wong
Second phase of auction for a prime retail development parcel in Chengdu, China. Competition forces the firm to revisit all of its land purchase criteria. Hang Lung Properties is known for rigorous due diligence, for discipline in buying property, and for good... View Details
- 2010
- Article
The Ethical Mirage: A Temporal Explanation as to Why We Are Not as Ethical as We Think We Are
By: A. E. Tenbrunsel, K. Diekmann, K A. Wade-Benzoni and Max Bazerman
This paper explores the biased perceptions that people hold of their own ethicality. We argue that the temporal trichotomy of prediction, action and recollection is central to these misperceptions: People predict that they will behave more ethically than they actually... View Details
- February 2010 (Revised May 2010)
- Supplement
Bardhaman (B): Bengal Shrachi and the Township Design Decision
By: John D. Macomber and Viraal Balsari
A real estate developer in West Bengal chooses between two master plans for a 260 acre new township considering design, financing, and phasing. Two detailed master plans are considered, one with a radial design and an internal town square and one with a grid design and... View Details
- 2007
- Working Paper
The Ethical Mirage: A Temporal Explanation as to Why We Aren't as Ethical as We Think We Are
By: Ann E. Tenbrunsel, Kristina A. Diekmann, Kimberly A. Wade-Benzoni and Max H. Bazerman
This paper explores the biased perceptions that people hold of their own ethicality. We argue that the temporal trichotomy of prediction, action and evaluation is central to these misperceptions: People predict that they will behave more ethically than they actually... View Details
- February 2005 (Revised March 2009)
- Case
Arauco (A): Forward Integration or Horizontal Expansion?
By: Ramon Casadesus-Masanell, Jorge Tarzijan and Jordan Mitchell
Celulosa Arauco is a major Chilean producer of market pulp and wood products. Owning over 1.2 million hectares of forest in Chile, Argentina, and Uruguay, the company's key advantage is the ideal growing conditions in which the company's forests are located. As of... View Details
- March 2004 (Revised June 2006)
- Case
Journey to Sakhalin: Royal Dutch/Shell in Russia (A)
By: Rawi E. Abdelal
Operations of Royal Dutch/Shell in Russia included a strategic alliance with Gazprom, the country's natural gas monopoly, the development of the Salym oil fields in Siberia, and a small retail refilling network in St. Petersburg. Focuses on the Sakhalin II project.... View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (B)
By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details
- April 2002
- Case
In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen
By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok
Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details
- December 2001
- Background Note
A Note on Critical Moments in Negotiation
By: Michael A. Wheeler and Gillian Morris
This case provides an introduction to the wide field of literature that addresses the presence of critical moments--moments that fundamentally can change the negotiation. Critical moments have been examined by a range of theorists and scientists, from mathematicians to... View Details
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
- October 2000 (Revised March 2003)
- Case
Merck & Company: Evaluating a Drug Licensing Opportunity
By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
- August 1995 (Revised August 1995)
- Case
CIGNA Property and Casualty Reengineering (A)
By: Richard L. Nolan, Donna B. Stoddard, Chiara Francalanci and Elise C Martin
Reengineering was introduced at CIGNA Corp. in 1988. CIGNA entered a second wave reengineering effort through a major project at CIGNA P&C, one of CIGNA's larger businesses. P&C was in financial crisis and as a result brought in a new executive team in 1991 to head the... View Details
- December 1991 (Revised October 1998)
- Case
Eli Lilly and Co.: Manufacturing Process Technology Strategy--1991
By: Gary P. Pisano, Steven C. Wheelwright and Jonathan West
Outlines the evolution of Lilly's corporate manufacturing strategy over the past decade. The corporate vice president of manufacturing must decide on the next phase of Lilly's strategy for the early 1990s, as well as to what extent and what role process development... View Details
- Research Summary
Overview
By: Iavor I. Bojinov
Over the last decade, technology companies like Amazon, Google, and Netflix have pioneered data-driven research and development processes centered on massive experimentation. However, as companies increase the breadth and scale of their experiments to millions of... View Details